Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Sirnaomics Ltd. ( ($HK:2257) ) has issued an announcement. Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

MISSISSAUGA, ON, Dec. 16, 2025 /CNW/ – Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...